[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, Du Y, Lewington V, Smart J, Thom J, Zivanovic M, Johnson PW: Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood; 2009 Feb 12;113(7):1412-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.
  • The effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown.
  • We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma.
  • Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009).
  • Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007).
  • Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy.
  • The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Iodine Radioisotopes / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Hemoglobins. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Spleen / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074729.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C328/A2738; United Kingdom / Cancer Research UK / / C431/A3313; United Kingdom / Department of Health / /
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Hemoglobins; 0 / Iodine Radioisotopes
  •  go-up   go-down


2. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H: Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol; 2007 Sep 1;179(5):2860-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.
  • However, inhibitory mechanisms, which function to limit the recall responses of tumor-specific immunity, remain poorly understood and interfere with therapies anticipated to induce protective immunity.
  • The mouse renal cell carcinoma (RENCA) tumor model was used to investigate variables affecting vaccination outcomes.
  • We demonstrate that although a whole cell irradiated tumor cell vaccine can trigger a functional antitumor memory response in the bone marrows of mice with established tumors, these responses do not culminate in the regression of established tumors.
  • In addition, a CD103+ regulatory T (Treg) cell subset accumulates within the draining lymph nodes of tumor-bearing mice.
  • Specifically, mice bearing large established RENCA tumors were treated with tumor cell vaccination in combination with B7-H1 blockade and CD4+ T cell depletion (triple therapy treatment) and monitored for tumor growth and survival.
  • Triple treatment therapy induced complete regression of large established RENCA tumors and raised long-lasting protective immunity.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / drug therapy. Immunologic Memory. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, CD / analysis. Antigens, CD274. Antigens, CD4 / analysis. Antigens, CD80. Bone Marrow Cells / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Dendritic Cells / immunology. Disease Models, Animal. Integrin alpha Chains / analysis. Lymphocyte Depletion. Membrane Glycoproteins / antagonists & inhibitors. Mice. Mice, Inbred Strains. Peptides / antagonists & inhibitors. Spleen / immunology. T-Lymphocytes, Regulatory / immunology. Vaccination

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709500.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, CD4; 0 / Antigens, CD80; 0 / Cancer Vaccines; 0 / Cd274 protein, mouse; 0 / Integrin alpha Chains; 0 / Membrane Glycoproteins; 0 / Peptides; 0 / alpha E integrins
  •  go-up   go-down


3. Ford RJ, Shen L, Lin-Lee YC, Pham LV, Multani A, Zhou HJ, Tamayo AT, Zhang C, Hawthorn L, Cowell JK, Ambrus JL Jr: Development of a murine model for blastoid variant mantle-cell lymphoma. Blood; 2007 Jun 1;109(11):4899-906
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a murine model for blastoid variant mantle-cell lymphoma.
  • Blastoid-variant mantle-cell lymphoma (MCL-BV), unlike most B-cell non-Hodgkin lymphomas (NHL-Bs), is refractory to conventional chemotherapy and associated with a very poor prognosis.
  • Development of new therapies has been hampered by the lack of valid animal models.
  • We have developed a novel murine model of MCL-BV by crossing interleukin 14alpha (IL-14alpha) transgenic mice with c-Myc transgenic mice (double transgenic [DTG]).
  • IL-14alpha is a B-cell growth factor that is expressed in a number of high-grade lymphomas, including MCL-BV.
  • Ninety-five percent of IL-14alpha transgenic mice develop CD5(+) large B-cell lymphomas by 18 months of age.
  • Sixty percent of c-Myc transgenic mice develop pre-B-cell lymphomas by 12 months of age.
  • Close to 100% of DTG mice develop an aggressive, rapidly fatal lymphoma at 3 to 4 months of age that is CD5(+), CD19(+), CD21(-), CD23(-), sIgM(+).
  • The tumor is found in the blood, bone marrow, liver, spleen, lymph nodes, gastrointestinal tract, and lungs and rarely in the brain, similar to the involvement seen in human MCL-BV.
  • DTG represents a novel model for MCL-BV that should reveal important insights into the pathogenesis of the lymphoma and contribute to the development of new forms of therapy.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2004 Feb;124(3):289-98 [14717775.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):49-54 [15061196.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6684-91 [15153484.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2505-13 [15226187.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] J Clin Invest. 1985 Feb;75(2):732-9 [2982918.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] EMBO J. 1989 Mar;8(3):749-55 [2785918.001]
  • [Cites] Oncogene Res. 1989;4(4):253-8 [2549487.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 15;166(2):101-11 [16631465.001]
  • [Cites] Leukemia. 2006 May;20(5):891-3 [16525491.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4540-8 [16497967.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5676-86 [17015757.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2087-93 [10602433.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):2200-6 [10657675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8 [10706620.001]
  • [Cites] Lab Invest. 2000 Apr;80(4):557-73 [10780672.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1183-90 [11034608.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):241-6 [11160144.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):56-62 [11753079.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1563-71 [12400598.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):434-41 [12580957.001]
  • [Cites] Annu Rev Immunol. 2003;21:841-94 [12615894.001]
  • [Cites] Nat Immunol. 2003 May;4(5):410-5 [12719730.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):330-5 [12733111.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):32-8 [12742154.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4283-94 [12773570.001]
  • [Cites] J Immunol. 2003 Jul 1;171(1):88-95 [12816986.001]
  • [Cites] Am J Clin Pathol. 1999 Apr;111(4):495-500 [10191769.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):171-7 [10319386.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1595-608 [2681271.001]
  • [Cites] J Immunol. 1990 Dec 15;145(12):3949-55 [2258603.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):871-89 [1938759.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6330-4 [8327514.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] EMBO J. 1994 Aug 1;13(15):3487-95 [8062825.001]
  • [Cites] Blood. 1995 Jul 1;86(1):283-93 [7795235.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):312-5 [8896561.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1324-35 [9032259.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):539-50 [9389361.001]
  • [Cites] Clin Immunol Immunopathol. 1998 Apr;87(1):42-9 [9576009.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):13-9 [16393691.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]
  • [Cites] Haematologica. 2006 Jan;91(1):40-7 [16434369.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352-7 [16461462.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):998-1007 [16247460.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):22-7 [16402392.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):759-72 [16410803.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):22033-40 [10419529.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):411-8 [15548996.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] Curr Hematol Rep. 2005 Jan;4(1):31-8 [15610657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4097-102 [15753301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4324-9 [15738393.001]
  • [Cites] J Pathol. 2005 Jun;206(2):123-34 [15880597.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4445-54 [15718413.001]
  • [Cites] Virchows Arch. 2005 May;446(5):475-82 [15856292.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):6225-34 [15988031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9613-8 [15983382.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):425-31 [16093790.001]
  • [Cites] Med Oncol. 2005;22(4):327-41 [16260850.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):121-7 [16321836.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):195-205 [16321849.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4315-21 [16123218.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):760-6 [14608904.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8226-32 [14678979.001]
  • (PMID = 17311992.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA 16672-26; United States / NCI NIH HHS / CA / R01 CA 100836
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Interleukin; 0 / interleukin-14 receptor
  • [Other-IDs] NLM/ PMC1885517
  •  go-up   go-down


Advertisement
4. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R, Dubinett SM: Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res; 2001 Sep 1;61(17):6406-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
  • The antitumor efficiency of secondary lymphoid organ chemokine (SLC), a CC chemokine that chemoattracts both dendritic cells (DCs) and T lymphocytes,was evaluated in SV40 large T-antigen transgenic mice that develop bilateral multifocal pulmonary adenocarcinomas.
  • Injection of recombinant SLC in the axillary lymph node region led to a marked reduction in tumor burden with extensive lymphocytic and DC infiltration of the tumors and enhanced survival.
  • SLC injection led to significant increases in CD4 and CD8 lymphocytes as well as DC at the tumor sites, lymph nodes, and spleen.
  • The cellular infiltrates were accompanied by the enhanced elaboration of Type 1 cytokines and the antiangiogenic chemokines IFN-gamma inducible protein 10, and monokine induced by IFN-gamma (MIG).
  • In contrast, lymph node and tumor site production of the immunosuppressive cytokine transforming growth factor beta was decreased in response to SLC treatment.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Angiogenesis Inhibitors / pharmacology. Chemokines, CC / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, Polyomavirus Transforming / genetics. Antigens, Polyomavirus Transforming / immunology. Chemokine CCL21. Chemokines / metabolism. Chemokines / secretion. Cytokines / metabolism. Cytokines / secretion. Dendritic Cells / drug effects. Dendritic Cells / immunology. Disease Models, Animal. Endothelial Growth Factors / metabolism. Lymph Nodes / cytology. Lymph Nodes / immunology. Lymphokines / metabolism. Mice. Mice, Transgenic. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / immunology. Neovascularization, Pathologic / metabolism. Recombinant Proteins / pharmacology. Spleen / cytology. Spleen / immunology. T-Lymphocytes / drug effects. T-Lymphocytes / immunology. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11522634.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 1P50 CA90388; United States / NCI NIH HHS / CA / R01 CA78654; United States / NCI NIH HHS / CA / R01 CA87879
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, Polyomavirus Transforming; 0 / Ccl21c protein, mouse; 0 / Chemokine CCL21; 0 / Chemokines; 0 / Chemokines, CC; 0 / Cytokines; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


5. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM: Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res; 2008 Jun 15;14(12):3966-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
  • Transforming growth factor-beta (TGF-beta) is one of the most important of these immunosuppressive factors because it affects both T-cell and macrophage functions.
  • We thus hypothesized that systemic blockade of TGF-beta signaling combined with adoptive T-cell transfer would enhance the effectiveness of the therapy.
  • EXPERIMENTAL DESIGN: Flank tumors were generated in mice using the chicken ovalbumin-expressing thymoma cell line, EG7.
  • Splenocytes from transgenic OT-1 mice (whose CD8 T cells recognize an immunodominant peptide in chicken ovalbumin) were activated in vitro and adoptively transferred into mice bearing large tumors in the presence or absence of an orally available TGF-beta receptor-I kinase blocker (SM16).
  • Additional investigation revealed that TGF-beta receptor blockade increased the persistence of adoptively transferred T cells in the spleen and lymph nodes, increased numbers of adoptively transferred T cells within tumors, increased activation of these infiltrating T cells, and altered the tumor microenvironment with a significant increase in tumor necrosis factor-alpha and decrease in arginase mRNA expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2006 May-Jun;29(3):250-60 [16699368.001]
  • [Cites] Immunol Lett. 2003 Mar 3;86(1):37-43 [12600743.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1733-43 [16891459.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4794-803 [16914564.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2749-61 [17116735.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53 [17255288.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2883-92 [17312132.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2351-9 [17332368.001]
  • [Cites] Annu Rev Immunol. 2007;25:243-65 [17129181.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1466-76 [17549249.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 [12427970.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1860-4 [12702574.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6838-46 [14583481.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):817-25 [15027114.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5839-49 [15313928.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6524-9 [15374963.001]
  • [Cites] Cell. 1988 Sep 9;54(6):777-85 [3261634.001]
  • [Cites] Int Immunol. 1992 Aug;4(8):861-7 [1419956.001]
  • [Cites] Jpn J Cancer Res. 1994 Nov;85(11):1137-43 [7829399.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5347-54 [9605134.001]
  • [Cites] Nat Med. 1999 Jun;5(6):677-85 [10371507.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1188-99 [10450746.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7209-16 [15585842.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1761-9 [15753372.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1061-7 [15809351.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5215-23 [15843517.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6074-83 [11342625.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5042-51 [11673513.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):143-54 [11900990.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] Blood. 2002 May 1;99(9):3179-87 [11964281.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9547-54 [16230420.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):96-103 [15891880.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11752-61 [16357188.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):30-7 [16377175.001]
  • [Cites] Annu Rev Immunol. 2006;24:99-146 [16551245.001]
  • [Cites] Curr Opin Immunol. 2006 Jun;18(3):363-70 [16616471.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):233-40 [16699366.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):241-9 [16699367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12457-61 [17640914.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2197-204 [17657310.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6247-51 [17975134.001]
  • [Cites] Immunol Rev. 2006 Oct;213:195-212 [16972905.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5527-36 [16740684.001]
  • (PMID = 18559619.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066726; United States / NCI NIH HHS / CA / CA066726-11; United States / NCI NIH HHS / CA / P01 CA 66726; United States / NCI NIH HHS / CA / T32 CA009140; United States / NCI NIH HHS / CA / T32 CA 09140; United States / NCI NIH HHS / CA / P01 CA066726-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azabicyclo Compounds; 0 / Receptors, Transforming Growth Factor beta; 0 / SM16 compound
  • [Other-IDs] NLM/ NIHMS56421; NLM/ PMC2491721
  •  go-up   go-down


6. Sudowe S, Ludwig-Portugall I, Montermann E, Ross R, Reske-Kunz AB: Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther; 2003 Oct;8(4):567-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses.
  • Biolistic transfection with pFascin initiated a marked type 1 immune response characterized by the occurrence of a large population of IFN-gamma-producing T helper (Th) cells in spleen and draining lymph nodes.
  • In contrast, the humoral response after repeated administration of pCMV was strongly enhanced and characterized by a type 2-like isotype pattern (IgG1 > IgG2a).
  • Cytokine production analysis in vitro indicated compartmentalization of the immune response, revealing large numbers of IL-4-producing Th cells in the lymph nodes and dominant presence of IFN-gamma-producing Th cells in the spleen.
  • Thus gene gun immunization with plasmids that focus transgene expression and antigen production specifically to DC propagates type 1-biased cellular immune responses.
  • [MeSH-major] Biolistics. Cancer Vaccines / immunology. Dendritic Cells / immunology. Neoplasms / drug therapy. Plasmids / immunology. Transcription, Genetic / immunology
  • [MeSH-minor] Cell Division / drug effects. Genes, Reporter. Genetic Vectors. Spleen / drug effects. Th1 Cells / drug effects. Th1 Cells / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529829.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


7. Meijer J, Zeelenberg IS, Sipos B, Roos E: The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res; 2006 Oct 1;66(19):9576-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chemokine receptor CXCR5 is expressed by B cells and certain T cells and controls their migration into and within lymph nodes.
  • Its ligand BCA-1/CXCL13 is present in lymph nodes and spleen and also in the liver.
  • Surprisingly, we detected CXCR5 in several mouse and human carcinoma cell lines.
  • CXCR5 was particularly prominent in pancreatic carcinoma cell lines and was also detected by immunohistochemistry in 7 of 18 human pancreatic carcinoma tissues.
  • We conclude that expression of CXCR5 on tumor cells promotes the growth of tumor cells in the liver and, at least for CT26 cells, seems to be required for outgrowth to large liver tumors.
  • Given the limited expression on normal cells, CXCR5 may constitute an attractive target for therapy, particularly for pancreatic carcinoma.
  • [MeSH-minor] Animals. Cell Line, Tumor / chemistry. Cell Line, Tumor / transplantation. Chemokine CXCL13. Chemokines, CXC / administration & dosage. Chemokines, CXC / pharmacology. Drug Delivery Systems. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Oligopeptides / administration & dosage. Organ Specificity. Pancreatic Neoplasms / chemistry. Protein Sorting Signals. Receptors, CXCR5. Recombinant Fusion Proteins / physiology. Spleen. Splenic Neoplasms / secondary. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - CXCR5 - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018614.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / CXCR5 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; 0 / Neoplasm Proteins; 0 / Oligopeptides; 0 / Protein Sorting Signals; 0 / Receptors, CXCR5; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins; 113516-56-6 / lysyl-aspartyl-glutamyl-leucine
  •  go-up   go-down


8. Audouin J, Vercelli-Retta J, Le Tourneau A, Adida C, Camilleri-Broët S, Molina T, Diebold J: Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis. Pathol Res Pract; 2003;199(2):107-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis.
  • We report an exceptional case of a histiocytic sarcoma presenting as a primary isolated spleen tumor in a 71-year-old woman.
  • The medium cells, large cells and the giant cells expressed CD68, a histiocyte-associated marker, lysozyme and S100 protein.
  • All these cells were negative for B- and T-cell markers, cytokeratins, melanosome markers (HMB45) and CD1a (Langerhans' cells).
  • Despite multi-agent chemotherapy, the patient suffered from a relapse in the liver, with a rapid fatal outcome.
  • In contrast, in systemic malignant histiocytosis, secondary spleen involvement occurs more frequently but with diffuse infiltration.
  • [MeSH-minor] Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inflammation / metabolism. Inflammation / pathology. Liver Neoplasms / secondary. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12747473.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Yagita K, Iwai M, Yagita-Toguri M, Kimura H, Taniwaki M, Misawa S, Okanoue T, Kashima K, Tsuchihashi Y: Langerhans cell histiocytosis of an adult with tumors in liver and spleen. Hepatogastroenterology; 2001 Mar-Apr;48(38):581-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Langerhans cell histiocytosis of an adult with tumors in liver and spleen.
  • We describe a 58-year-old male with multiple histiocytic tumors in the liver and spleen.
  • Multiple tumors in the liver and spleen were seen by image analysis, and splenectomy showed a large splenic tumor with a small nodule and a swelling lymph node in the hilus.
  • Histological features of the tumors in the liver and spleen revealed proliferation of histiocytic cells with large and clear cytoplasm and a horseshoe-shaped nucleus.
  • No definite Birbeck granules were seen ultrastructurally, thus the tumor cells could be classified into Langerhans cell type without Birbeck granules.
  • Administration of adriamycin, vincristine, cyclophosphamide and prednisolone reduced size and number of the liver tumors, and the histiocytic cells could not be detected in repeatedly biopsied tissue from liver tumor.
  • We present the clinical, immunohistological and cytological features in a visceral type of adult Langerhans cell histiocytosis, which responded well to chemotherapy.
  • [MeSH-major] Histiocytosis, Langerhans-Cell / complications. Liver Neoplasms / complications. Splenic Neoplasms / complications
  • [MeSH-minor] Antigens, CD1 / metabolism. Histiocytes / ultrastructure. Humans. Immunohistochemistry. Male. Middle Aged. S100 Proteins / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379359.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / CD1a antigen; 0 / S100 Proteins
  •  go-up   go-down


10. Hasegawa H, Katano H, Tanno M, Masuo S, Ae T, Sato Y, Takahashi H, Iwasaki T, Kurata T, Sata T: BCL-6-positive human herpesvirus 8-associated solid lymphoma arising from liver and spleen as multiple nodular lesions. Leuk Lymphoma; 2004 Oct;45(10):2169-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCL-6-positive human herpesvirus 8-associated solid lymphoma arising from liver and spleen as multiple nodular lesions.
  • We report a case of BCL-6-positive B cell lymphoma with human herpesvirus 8 (HHV-8) infection.
  • A human immunodeficiency virus-infected patient developed a diffuse large B cell lymphoma, which was found exclusively in the liver and spleen with the absence of lymphadenopathy and effusion in any body cavities.
  • The lymphoma cells were composed of medium to large-sized cells positive for CD20, CD45, and BCL-6, and negative for epithelial cell membrane antigen, CD30, CD45RO, and CD138/syndecan-1, suggesting a germinal center B cell origin.
  • The patient was serologically positive for HHV-8, and HHV-8 was detected in the liver biopsy tissue both by polymerase chain reaction and by immunohistochemistry for HHV-8-encoded latency-associated nuclear antigen.
  • Other HHV-8-associated diseases, such as Kaposi's sarcoma, primary effusion lymphoma, or multicentric Castleman's disease were not detected in the patient.
  • Chemotherapy was effective and reduced the size of the lymphoma dramatically.
  • This is the first case report of a germinal center B cell-originating lymphoma with HHV-8 infection.
  • [MeSH-major] DNA-Binding Proteins / analysis. Herpesviridae Infections / complications. Herpesvirus 8, Human. Liver Neoplasms / virology. Lymphoma, B-Cell / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinal Center / pathology. Germinal Center / virology. HIV Infections / complications. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370268.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  •  go-up   go-down


11. Candoni A, Trevisan R, Filì C, Tiribelli M, Fanin R: Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. J Infect Chemother; 2004 Oct;10(5):303-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma.
  • Here we report a rare case of Hafnia alvei septicemia with an abdominal abscess in a 60-year-old woman with diffuse large B-cell lymphoma involving the spleen, liver, and then lymph nodes.
  • She initially received a splenectomy, and, over a 2-year period, four courses of chemotherapy.
  • After achieving complete remission status, she underwent autologous peripheral blood stem-cell transplantation (PBSCT).
  • During the aplastic phase following transplantation, the patient developed fever, diarrhea, and abdominal pain, with blood cultures positive for Hafnia alvei and an abscess in the splenic recess.
  • Considering the high surgical risk, the infection was treated, successfully, with antibiotics (imipenem/cilastatin), without surgery or computed tomography (CT)-guided percutaneous drainage.
  • Infections due to Hafnia alvei are rare, and this is the first reported case of Hafnia alvei septicemia in an adult hematologic patient undergoing a stem-cell transplantation procedure.
  • [MeSH-major] Abdominal Abscess / microbiology. Bacteremia / microbiology. Hafnia alvei / isolation & purification. Lymphoma, B-Cell / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Enterobacteriaceae Infections / microbiology. Female. Hepatitis C / complications. Humans. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Transplantation, Autologous / adverse effects

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163467.001).
  • [ISSN] 1341-321X
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Manz MG, Berger C, Horny HP, Beck R, Brugger W, Viebahn R, Kanz L, Knecht H: Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipient. Transplantation; 2002 Mar 27;73(6):995-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipient.
  • BACKGROUND: Epstein-Barr virus associated posttransplant high-grade large cell lymphoma (EBV-PTL) is thought to be incurable solely by cessation of immunosuppression.
  • A strong cytotoxic memory T cell (CTL) reaction against two individual recipient EBV strains appears to be involved.
  • RESULTS: Stage IIIB EBV-PTL of recipient type was cured through strong autologous CTL reaction consecutive to alleviation of immunosuppression.
  • Latent membrane protein 1 fingerprinting identified three different EBV strains; namely in lymphoma and peripheral lymphocytes of donor and recipient.
  • [MeSH-major] Diabetes Mellitus, Type 1 / surgery. Herpesvirus 4, Human / isolation & purification. Kidney Transplantation. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pancreas Transplantation
  • [MeSH-minor] Adult. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Lymph Nodes / pathology. Male. Postoperative Complications. Reoperation. Spleen / virology. Tissue Donors. Treatment Outcome


13. Sano T, Sakai H, Takimoto K, Ohno H: Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome. Int J Clin Oncol; 2007 Feb;12(1):59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
  • We report here the case of a 63-year-old man who had a diffuse large B-cell lymphoma associated with hemophagocytic syndrome (HPS).
  • The lymphoma involved the spleen, bilateral adrenal glands, and paraaortic lymph nodes of the abdomen.
  • In both the bone marrow and lymph nodes, hemophagocytosis was evident, and the laboratory findings were consistent with HPS.
  • The lymphoma cells showed a CD4+, CD5+, CD10-, CD19+, CD20+, CD25+ and surface immunoglobulin microalpha/kappa+ immunophenotype.
  • The patient was unintentionally treated with rituximab alone, resulting in complete resolution of the lymphomatous lesions as well as the features of HPS in response to the initial two doses of rituximab, although he developed gastric hemorrhage requiring vigorous resuscitation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / complications. Abdominal Neoplasms / drug therapy. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / drug therapy. Antibodies, Monoclonal, Murine-Derived. Humans. Lymphatic Metastasis. Male. Middle Aged. Rituximab. Splenic Neoplasms / complications. Splenic Neoplasms / drug therapy. Transcription Factor CHOP / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Ann Oncol. 2004 May;15(5):821-30 [15111353.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1658-64 [12886256.001]
  • [Cites] Leuk Lymphoma. 2000 Jun;38(1-2):121-30 [10811454.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):656-64 [9401080.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):411-9 [12512835.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):983-8 [9796727.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):928-34 [10533473.001]
  • [Cites] Int J Hematol. 2003 Apr;77(3):286-94 [12731674.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1644-52 [9473230.001]
  • (PMID = 17380444.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / DDIT3 protein, human; 147336-12-7 / Transcription Factor CHOP; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Sawada M, Yamada T, Tsurumi H, Moriwaki H: [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy]. Rinsho Ketsueki; 2002 Nov;43(11):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy].
  • A biopsy showed diffuse proliferation of large atypical lymphocytes, which were positive for CD45RO, CD56, MIB-1, and EBER.
  • A diagnosis of nasal NK cell lymphoma with hemophagocytic syndrome (clinical stage IVB) was made.
  • Following CHOP regimen chemotherapy, the tumor transiently reduced in size, but the patient developed multiple organ failure possibly due to tumor lysis syndrome.
  • His general condition was improved by intensive supporting therapy.
  • Despite salvage chemotherapy with a P-IMVP16/CBDCA regimen, the patient died of multiple organ failure due to tumor lysis syndrome.
  • Autopsy revealed diffuse necrosis and fibrosis without proliferation of lymphoma cells in the liver, spleen, bone marrow, and lymph nodes.
  • The poor prognosis of NK/T cell lymphoma might be associated with massive tissue damage with hypercytokinemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Histiocytosis, Non-Langerhans-Cell / etiology. Killer Cells, Natural. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy. Prednisone / adverse effects. Tumor Lysis Syndrome / etiology. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508484.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Natkunam Y, Stanton TS, Warnke RA, Horning SJ: Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab. Clin Lymphoma; 2001 Dec;2(3):185-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
  • A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma.
  • While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment.
  • We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunophenotyping. Liver / drug effects. Liver / pathology. Liver / radiography. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab. Spleen / drug effects. Spleen / pathology. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779297.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Hasegawa Y, Shirai S, Mishina T, Nakata M, Aikawa K, Yoshida K: [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart]. Rinsho Ketsueki; 2002 Jul;43(7):538-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart].
  • We report on an elderly patient with a malignant lymphoma forming a huge mass in the heart.
  • Her right supraclavicular, bilateral axillary, and right inguinal lymph nodes were swollen.
  • Her left axillary lymph node was biopsied.
  • She was diagnosed as having non-Hodgkin lymphoma, diffuse large cell type, B-cell type.
  • Computed tomography scans showed a markedly thickened right ventricular wall of the heart, swollen lymph nodes of the mediastinum, bilateral pleural effusions, and a tumor in the spleen.
  • Lymphoma cells were found in the pleural effusion, and the lymphoma was diagnosed as clinical stage IV.
  • EF increased to 70% after 3 courses of chemotherapy with CHOP regimen.
  • All lesions disappeared after 6 courses of chemotherapy were completed.
  • After consolidative radiotherapy with a total dose of 37 Gy to the mediastinum and heart, bilateral pleural effusions, elevation of the patient's lactate dehydrogenase level and soluble IL-2 receptor value were recognized, which suggested relapse of the lymphoma, although histopathological confirmation could not be realized.
  • [MeSH-major] Heart Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Heart tumor.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229122.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Kojima H, Shimizu S, Yoshida C, Katsura Y, Suzukawa K, Mukai HY, Hasgawa Y, Imagawa S, Mori N, Nagasawa T: Rapidly progressive Lennert's lymphoma terminating in fulminant hepatic failure. Leuk Lymphoma; 2003 Aug;44(8):1409-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressive Lennert's lymphoma terminating in fulminant hepatic failure.
  • A 65-year-old male with rapidly progressive Lennert's lymphoma terminating in fulminant hepatic failure is presented.
  • Staging radiological studies revealed that he had cervical and mediastinal lymph node swellings and multiple nodular lesions in the spleen.
  • Lymph node biopsy specimens showed the proliferation of epithelioid cells interspersed with large blastic lymphocytes.
  • These lymphocytes were CD3+, CD45RO (UCHL-1) +, CD4-, CD8+, CD56-, CD30-, CD15-, T-cell intracellular antigen-1+, granzyme B+ and perforin+, suggestive of the cytotoxic T-cell lineage.
  • Under the diagnosis of Lennert's lymphoma, he was treated with standard CHOP chemotherapy.
  • After two courses of the chemotherapy, despite the decreased size of cervical lymph nodes, high-grade fever and constitutional symptoms appeared.
  • As multiple low-density nodules were observed in the liver by computed tomography, needle biopsy was performed.
  • The biopsy specimens showed the proliferation of CD3+, CD4- and CD8+ lymphoma cells.
  • This case is another example demonstrating that at least some of the Lennert's lymphomas phenotypically correspond with cytotoxic T-cell lymphomas, as was previously suggested by us [Am. J. Surg. Pathol.
  • It should be also emphasized that Lennert's lymphomas containing cytotoxic proteins may have a fulminant clinical course, which cannot be rescued by the conventional chemotherapy.
  • [MeSH-major] Liver Failure / etiology. Lymphoma, T-Cell / complications
  • [MeSH-minor] Aged. Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Lineage. Disease Progression. Fatal Outcome. Humans. Liver Neoplasms / pathology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Neoplasm Invasiveness / pathology. T-Lymphocytes, Cytotoxic / pathology. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12952236.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


18. Yoshida M, Nishikawa Y, Yamamoto Y, Doi Y, Tokairin T, Yoshioka T, Omori Y, Watanabe A, Takahashi N, Yoshioka T, Miura I, Sawada K, Enomoto K: Mast cell leukemia with rapidly progressing portal hypertension. Pathol Int; 2009 Nov;59(11):817-22
Genetic Alliance. consumer health - Portal hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell leukemia with rapidly progressing portal hypertension.
  • Reported herein is an autopsy case of mast cell leukemia, a rare form of systemic mastocytosis, complicated with portal hypertension.
  • Chemotherapy with cytosine arabinoside and idarubicin was ineffective and the patient died of multi-organ failure with rapidly progressing hepatosplenomegaly and large-volume ascites 3 months after admission.
  • At autopsy the bone marrow, spleen, liver, and lymph nodes were extensively infiltrated by atypical tumor cells with occasional bi- or multi-lobated nuclei.
  • They were positive for mast cell tryptase and possessed an activating mutation of the c-kitgene (D816V).
  • Although there was no evidence of liver cirrhosis, the hepatic sinusoids were clogged with tumor cells, with a tendency to be more severe in the perivenular areas, and the lumens of central veins were obliterated by tumor cell infiltration.
  • The present case demonstrates that non-cirrhotic portal hypertension due to blocking of sinusoidal and venous flow could be a serious complication in mast cell leukemia.
  • [MeSH-major] Hypertension, Portal / etiology. Leukemia, Mast-Cell / complications

  • Genetic Alliance. consumer health - Leukemia, mast-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883434.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


19. Ikenoue Y, Tagami T, Murata M: Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol; 2005 Jun;5(6):993-1006
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and validation of a novel IL-10 deficient cell transfer model for colitis.
  • A number of rodent models for inflammatory bowel disease (IBD) have been developed, but most cannot be used to develop and validate new therapies for IBD.
  • From the models developed, the IL-10 deficient mouse model is the one that results in a disease similar to human IBD; however, in this model, colitis occurs with variable incidence taking 3-4 months to develop.
  • These are serious problems with the model when evaluating a new therapy because of the large-scale experiments required and the difficulty in performing an accurate pharmacological analysis.
  • In this study, the IL-10 deficient mouse model was modified by transferring whole spleen and mesenteric lymph node cells from IL-10 deficient mice to CB-17 SCID mice.
  • In this IL-10 deficient cell transfer model, chronic intestinal inflammation developed in all recipients within 2-3 weeks, which was far earlier than in donor IL-10 deficient mice.
  • The pathological phenotypes were similar to those of IL-10 deficient mice and CD45RBhi T cell-transfer models.
  • In addition, we assessed several agents for inflammatory bowel disease to validate the general utility of this cell transfer model.
  • It is worth noting that TNFR-Ig or prednisolone, which is effective for treatment of patients with severe-fulminant Crohn's disease, markedly attenuated pathological clinical indices in this colitis model, whereas the immunosuppressive agents, azathioprine, tacrolimus, and cyclosporine A produced no significant effect.
  • These results suggest that the IL-10 deficient cell transfer model is a good experimental model to use for developing new and effective therapies for active IBD.
  • [MeSH-major] Cell Transplantation / methods. Inflammatory Bowel Diseases / genetics. Inflammatory Bowel Diseases / pathology. Interleukin-10 / physiology
  • [MeSH-minor] Adrenal Cortex Hormones / pharmacology. Animals. Antibodies, Monoclonal / pharmacology. Disease Models, Animal. Flow Cytometry. Immunosuppressive Agents / pharmacology. Lymph Nodes / cytology. Lymph Nodes / transplantation. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, SCID. Nitrates / blood. Nitrites / blood. Prednisolone / pharmacology. Reproducibility of Results. Spleen / cytology. Spleen / transplantation. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829415.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Monoclonal; 0 / Immunosuppressive Agents; 0 / Nitrates; 0 / Nitrites; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


20. Takai K, Nikkuni K, Sanada M, Shibuya H: [EB virus-associated peripheral T cell lymphoma presenting with hemophagocytic syndrome and hepatic cell necrosis]. Rinsho Ketsueki; 2003 Jul;44(7):462-7
Genetic Alliance. consumer health - Virus associated hemophagocytic syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [EB virus-associated peripheral T cell lymphoma presenting with hemophagocytic syndrome and hepatic cell necrosis].
  • Bone marrow aspiration showed infiltration of large atypical lymphoid cells and hemophagocytic histiocytes, thus suggesting a diagnosis of lymphoma associated hemophagocytic syndrome (LAHS).
  • Histologically, the cervical biopsy showed lymphoma cell infiltration with prominent necrosis and karyorrhectic debris.
  • The lymphoma cells expressed CD3+, CD4-, CD8+, CD20-, CD56+/-, TIA-1+, granzyme B+, and EBER was positive using in situ hybridization.
  • These findings were compatible with those of EB-virus associated peripheral T-cell lymphoma.
  • After chemotherapy with the THP-COP regimen, the patient's liver dysfunction improved rapidly, but she died from bacterial peritonitis due to perforation of a recurrent duodenal ulcer.
  • Post-mortem examination of the liver showed multiple irregular massive necroses of the hepatocytes, where no lymphoma cell infiltration was present.
  • Hemophagocytic histiocytosis was remarkable in the bone marrow, spleen, lymph nodes, and liver.
  • Marked elevation of serum levels of cytokines such as TNF-alpha or IFN-gamma suggests that these cytokines played an important role in the pathogenesis of the hepatic cell necrosis.
  • [MeSH-major] Epstein-Barr Virus Infections / etiology. Hepatocytes / pathology. Histiocytosis, Non-Langerhans-Cell / complications. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931565.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


21. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioedema: first manifestation of non-Hodgkin's lymphoma].
  • In a 48-year-old male patient a diagnosis of a non-Hodgkin lymphoma was made after two episodes of angioedema.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


22. Brouet JC: [Waldenström's macroglobulinemia]. Rev Prat; 2006 Jan 15;56(1):25-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenström's macroglobulinemia associates a serum monoclonal IgM and a lymphoplasmacytic infiltration of bone marrow, spleen, lymph nodes and various organs.
  • Major complications include bone marrow failure, auto-immune cytopenia, occurrence of large cell lymphoma and infections (related either to the humoral immunodeficiency or to chemotherapy).
  • Asymptomatic macroglobulinemia does not deserve any treatment.
  • The benefit of monoclonal antibodies, high dose chemotherapy followed by auto or allogenic stem cell graft is currently assessed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548246.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin M
  • [Number-of-references] 10
  •  go-up   go-down


23. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB: 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound; 2009 Mar-Apr;50(2):215-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor.
  • Positron Emission Tomography (PET) using the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) is a common imaging modality for diagnosis and management of many human malignancies.
  • We evaluated 18FDG-PET in dogs with either multicentric lymphoma (LSA) or cutaneous mast cell tumor (MCT).
  • A prototype large field-of-view PET scanner was used to collect whole-body images in nine dogs with LSA or MCT.
  • In dogs with LSA, 18FDG-PET correctly identified involvement of superficial and internal lymph nodes, liver, and spleen.
  • Repeated PET scans after induction chemotherapy demonstrated resolution of abnormal 18FDG uptake within these sites.
  • In dogs with MCT, 18FDG-PET correctly identified MCT metastasis to regional lymph nodes in all dogs in which this was suspected or confirmed with cytology or biopsy before the PET scan.
  • In two dogs, additional sites of mast cell disease were identified with 18FDG-PET that were undetected on physical examination and/or regional lymph node cytology.
  • [MeSH-major] Dog Diseases / radionuclide imaging. Lymphoma / veterinary. Mastocytoma, Skin / veterinary. Neoplasm Staging / veterinary. Positron-Emission Tomography / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400472.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Nadrous HF, Krowka MJ, McClure RF, Tefferi A, Lim KG: Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformation. Leuk Lymphoma; 2004 Apr;45(4):815-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Agnogenic myeloid metaplasia (AMM) is one of the myeloproliferative disorders, and is usually accompanied by extramedullary hematopoiesis (EMH) in various organs, mainly in the liver, spleen and lymph nodes.
  • EMH involving the lungs and pleura was suspected.
  • The diagnostic thoracentesis yielded bloody fluid that contained a large population of myeloblasts, indicating pleural leukemic transformation.
  • The patient received 100 cGy to the whole lung for treatment of pulmonary hypertension due to EMH.
  • Three months later he had leukemic transformation involving the skin and lymph nodes.
  • Four months after radiation therapy, he had full-blown acute myeloid leukemia.
  • Three months after initiation of chemotherapy, he deteriorated and received salvage chemotherapy of prednisone, VP-16 and imatinib mesylate (Gleevec).
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / etiology. Cell Transformation, Neoplastic. Fatal Outcome. Humans. Hypertension, Pulmonary / etiology. Hypertension, Pulmonary / radiotherapy. Male. Multiple Organ Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15160962.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Späth-Schwalbe E, Flath B, Kaufmann O, Thiel G, Brinckmann R, Dietel M, Possinger K: An unusual case of leukemic non-Hodgkin's lymphoma with blastic transformation. Ann Hematol; 2000 Apr;79(4):217-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of leukemic non-Hodgkin's lymphoma with blastic transformation.
  • We report on a patient who was diagnosed as having B-cell chronic lymphocytic leukemia (CLL) with atypical morphology.
  • Histology of the spleen and bone marrow suggested a diagnosis of small lymphocytic lymphoma.
  • Lymphoid blasts appeared in the peripheral blood, and the patient developed nodular infiltrates consisting of these blasts at recent venous puncture sites.
  • The patient did not respond to chemotherapy and died.
  • To account for the possibility of two independent lymphoid malignancies, molecular genetic analyses were performed on samples from the spleen, bone marrow and a lymph node with the large-cell lymphoma, which showed identical clones in these tissues.
  • This unusual case supports the idea that in leukemic non-Hodgkin's lymphoma, in addition to morphology, an accurate diagnostic workup requires immunophenotypic, cytogenetic, and molecular studies.
  • [MeSH-major] Leukemic Infiltration / pathology. Lymphocyte Activation / physiology. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834510.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


26. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC: Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol; 2004;112(4):203-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.
  • Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001.
  • The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient.
  • Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma.
  • Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma.
  • Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome.
  • All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment.
  • Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients.
  • These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy.
  • One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease.
  • Thus, salivary gland lymphoma proved to be an indolent disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Autoimmune Diseases / complications. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / complications. Male. Middle Aged. Radiotherapy. Remission Induction. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564732.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Chantakru S, Wang WC, van den Heuvel M, Bashar S, Simpson A, Chen Q, Croy BA, Evans SS: Coordinate regulation of lymphocyte-endothelial interactions by pregnancy-associated hormones. J Immunol; 2003 Oct 15;171(8):4011-9
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mouse uterine tissue, pregnancy markedly up-regulates both L-selectin- and alpha(4) integrin-dependent adhesion pathways for circulating human CD56(bright) cells, the phenotype of human uterine NK cells.
  • Based on roles for these adhesion molecules in lymphocyte homing, we examined effects of pregnancy or the steroid hormones 17beta-estradiol or progesterone on lymphocyte-endothelial interactions in secondary lymphoid tissues and in uterus.
  • From preimplantation gestation day 3, specialized high endothelial venules in peripheral lymph nodes and Peyer's patches supported elevated L-selectin and alpha(4)beta(7) integrin-dependent lymphocyte adhesion under shear throughout pregnancy, as compared with high endothelial venules of virgin or postpartum donors.
  • Squamous endothelium from nonlymphoid tissue was not affected.
  • Pregnancy-equivalent endothelial responses were observed in lymph nodes and Peyer's patches from ovariectomized mice receiving 17beta-estradiol and/or progesterone replacement therapy.
  • Adhesion of human CD56(bright) cells to uteri from pregnant or hormone-treated ovariectomized mice was enhanced through L-selectin- and alpha(4) integrin-dependent mechanisms and involved multiple vascular adhesion molecules including mucosal addressin cell adhesion molecule-1, VCAM-1, and peripheral lymph node addressin.
  • Microdomain localization of adhesion involving large clusters of lymphocytes was induced on uteri from natural matings, but not pseudopregnancy.

  • Genetic Alliance. consumer health - Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1983 Jul 7-13;304(5921):30-4 [6866086.001]
  • [Cites] J Biol Chem. 1987 Aug 25;262(24):11478-85 [3497921.001]
  • [Cites] Nature. 1988 Jan 7;331(6151):41-6 [3340147.001]
  • [Cites] J Cell Biol. 1988 Nov;107(5):1853-62 [2460470.001]
  • [Cites] Adv Anat Embryol Cell Biol. 1989;115:1-112 [2658485.001]
  • [Cites] Cell. 1990 Jan 12;60(1):53-61 [2295088.001]
  • [Cites] Cell. 1990 Feb 23;60(4):577-84 [1689216.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(6):2244-8 [2179952.001]
  • [Cites] Reprod Fertil Dev. 1992;4(5):565-71 [1299831.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):17-25 [7506711.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):94-101 [8041123.001]
  • [Cites] J Immunol. 1994 Nov 1;153(9):3847-61 [7523506.001]
  • [Cites] Blood Cells. 1994;20(1):25-44 [7527678.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2482-8 [7593638.001]
  • [Cites] Cell Immunol. 1995 Nov;166(1):53-61 [7585981.001]
  • [Cites] Cell Immunol. 1996 Jan 10;167(1):79-85 [8548848.001]
  • [Cites] J Leukoc Biol. 1996 Feb;59(2):262-9 [8603999.001]
  • [Cites] Hum Reprod. 1996 May;11(5):1079-82 [8671394.001]
  • [Cites] Hum Reprod. 1995 Dec;10(12):3272-9 [8822457.001]
  • [Cites] J Reprod Immunol. 1996 Aug;31(1-2):37-50 [8887121.001]
  • [Cites] Biol Reprod. 1997 Jan;56(1):169-79 [9002646.001]
  • [Cites] Obstet Gynecol. 1997 Mar;89(3):398-402 [9052593.001]
  • [Cites] J Reprod Immunol. 1997 Feb;32(3):241-63 [9080386.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2139-51 [9151786.001]
  • [Cites] Biochem Soc Trans. 1997 May;25(2):428-33 [9191130.001]
  • [Cites] Biol Reprod. 1997 Sep;57(3):495-506 [9282982.001]
  • [Cites] Am J Reprod Immunol. 1997 Dec;38(6):423-30 [9412726.001]
  • [Cites] J Immunol. 1998 Jan 15;160(2):961-9 [9551935.001]
  • [Cites] J Immunol. 1998 Jul 1;161(1):400-8 [9647249.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1593-602 [9802971.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):2185-92 [9890981.001]
  • [Cites] J Immunol. 1999 Mar 15;162(6):3615-24 [10092822.001]
  • [Cites] Eur J Immunol. 1999 Apr;29(4):1116-26 [10229078.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2704-10 [10342861.001]
  • [Cites] Adv Immunol. 1999;72:209-53 [10361577.001]
  • [Cites] Microcirculation. 1999 Jun;6(2):127-40 [10466115.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):935-42 [10510083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12021-6 [10518569.001]
  • [Cites] Int J Hyperthermia. 2000 Jan-Feb;16(1):45-59 [10669316.001]
  • [Cites] Hum Reprod Update. 2000 Jan-Feb;6(1):28-36 [10711827.001]
  • [Cites] Semin Cell Dev Biol. 2000 Apr;11(2):127-37 [10873709.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):259-70 [10899912.001]
  • [Cites] J Reprod Fertil. 2000 Sep;120(1):125-34 [11006154.001]
  • [Cites] Genesis. 2000 Oct;28(2):75-81 [11064424.001]
  • [Cites] Gynecol Endocrinol. 2001 Feb;15(1):29-33 [11293921.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1823-34 [11297624.001]
  • [Cites] Blood. 2001 May 1;97(9):2727-33 [11313264.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):22-8 [11751942.001]
  • [Cites] Biol Reprod. 2002 Feb;66(2):333-45 [11804946.001]
  • [Cites] Exp Mol Pathol. 2002 Apr;72(2):91-114 [11890719.001]
  • [Cites] Cell Immunol. 2001 Nov 25;214(1):12-20 [11902825.001]
  • [Cites] Life Sci. 2002 May 24;71(1):15-29 [12020745.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1869-73 [12016203.001]
  • [Cites] J Matern Fetal Neonatal Med. 2002 Jul;12(1):19-27 [12422905.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):440-9 [12519888.001]
  • [Cites] Science. 2003 Jan 17;299(5605):405-8 [12532021.001]
  • [Cites] Placenta. 2003 Apr;24(4):403-11 [12657515.001]
  • [Cites] Biol Reprod. 1972 Aug;7(1):82-6 [5050152.001]
  • [Cites] Arch Biochem Biophys. 1975 Jul;169(1):181-91 [1164021.001]
  • [Cites] Clin Exp Immunol. 1978 Mar;31(3):397-407 [657586.001]
  • [Cites] Arch Histol Jpn. 1980 Dec;43(5):423-36 [7235869.001]
  • (PMID = 14530321.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] None / None / / 67956; United States / NCI NIH HHS / CA / R01 CA079765; Canada / Canadian Institutes of Health Research / / 67956; United States / NCI NIH HHS / CA / CA79765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ CAMS1491; NLM/ PMC2967521
  •  go-up   go-down


28. Ou J, Yang L, Ren L, Tang X, Li T, Wu S: [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma]. Zhonghua Nei Ke Za Zhi; 2002 Jan;41(1):28-30
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features and tumor cells characteristics of splenic marginal zone lymphoma].
  • OBJECTIVE: To deepen the understanding of splenic marginal zone lymphoma (SMZL) and improve the level of diagnosis and therapy.
  • The pathologic, immunologic and genetic features of tumor cells in peripheral blood, bone marrow and spleen were studied with light microscopy, phase contrast microscopy, scanning electron microscopy, immunohistochemical method, flow cytometry, G chromosome banding technique and PCR for studying the pattern of IgH gene rearrangement.
  • RESULTS: The spleen was large with uniform parenchyma and smooth surface.
  • Lymph nodes in the splenic hilum were infiltrated by tumor cells.
  • The monoclonal pattern of IgH gene rearrangement in peripheral blood and bone marrow was found to be the same as that in spleen.
  • After splenectomy, COP chemotherapy and IFNalpha-2a were given and the abnormally increased lymphocytes decreased to normal level.
  • CONCLUSION: Splenomegaly, lymphocytosis in peripheral blood and bone marrow without lymph node enlargement and leukocytosis are clinical characters of SMZL.
  • [MeSH-major] Germinal Center / pathology. Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD20 / biosynthesis. Antigens, CD45 / biosynthesis. Cyclophosphamide / therapeutic use. Female. Gene Rearrangement. HLA-DR Antigens / biosynthesis. Humans. Immunoglobulin Heavy Chains / genetics. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Splenectomy. Splenomegaly / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11940293.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / HLA-DR Antigens; 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


29. Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE: Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res; 2010 Jan 15;16(2):727-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Interleukin-7 (IL-7) has critical and nonredundant roles in T-cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine.
  • Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immunosenescence), pathologic (HIV), or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant), and may have roles in immune reconstitution or enhancement of immunotherapy.
  • RESULTS: Mild to moderate constitutional symptoms, reversible spleen and lymph node enlargement, and marked increase in peripheral CD3(+), CD4(+), and CD8(+) lymphocytes were seen in a dose-dependent and age-independent manner in all subjects receiving >or=10 microg/kg/dose, resulting in a rejuvenated circulating T-cell profile, resembling that seen earlier in life.
  • CONCLUSION: This study shows the potent biological activity of rhIL-7 in humans over a well-tolerated dose range and allows further exploration of its possible therapeutic applications.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2007 May;123(2):155-65 [17320482.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Blood. 2000 Jul 1;96(1):9-23 [10891425.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1491-7 [11222398.001]
  • [Cites] Nat Immunol. 2000 Nov;1(5):426-32 [11062503.001]
  • [Cites] Blood. 2001 May 15;97(10):2983-90 [11342421.001]
  • [Cites] Blood. 2001 Aug 1;98(3):579-85 [11468153.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2256-65 [11568014.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(9):865-71 [11781647.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3892-904 [12010786.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):629-33 [12028034.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1311-8 [12094255.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2294-9 [12411295.001]
  • [Cites] Blood. 2003 May 15;101(10):4209-18 [12543864.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1534-40 [12714515.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1095-107 [14523046.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):258-68 [7506577.001]
  • [Cites] J Immunol. 1994 Jun 15;152(12):5776-84 [8207207.001]
  • [Cites] Immunol Ser. 1994;61:95-104 [8011760.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):58-67 [7527823.001]
  • [Cites] J Leukoc Biol. 1995 Dec;58(6):623-33 [7499959.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1887-94 [8781449.001]
  • [Cites] Bone Marrow Transplant. 1997 Mar;19(6):539-43 [9085732.001]
  • [Cites] Vaccine. 1997 Apr;15(5):561-3 [9160525.001]
  • [Cites] Immunol Rev. 1997 Jun;157:167-76 [9255629.001]
  • [Cites] Bone Marrow Transplant. 1999 Apr;23(8):783-8 [10231140.001]
  • [Cites] Cytokine Growth Factor Rev. 1999 Mar;10(1):41-60 [10379911.001]
  • [Cites] Cytokines Cell Mol Ther. 1999 Mar;5(1):25-39 [10390077.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4390-8 [15701725.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10569-77 [16288050.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7325-31 [16301638.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):914-22 [16393976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2262-7 [16461915.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):313-9 [16699374.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1693-700 [16818676.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1701-14 [18573906.001]
  • (PMID = 20068111.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / PHS HHS / / 01649
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / IL7 protein, human; 0 / Interleukin-7; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ NIHMS159582; NLM/ PMC2808195
  •  go-up   go-down


30. Stern JN, Illés Z, Reddy J, Keskin DB, Fridkis-Hareli M, Kuchroo VK, Strominger JL: Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A; 2005 Feb 1;102(5):1620-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction.

  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1995 Oct;3(4):397-405 [7584131.001]
  • [Cites] Neurology. 1995 Jul;45(7):1268-76 [7617181.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 31;795:216-26 [8958933.001]
  • [Cites] Eur J Immunol. 1997 Nov;27(11):3059-69 [9394837.001]
  • [Cites] Neurology. 1998 Mar;50(3):701-8 [9521260.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4386-97 [9574543.001]
  • [Cites] Braz J Med Biol Res. 1998 Jan;31(1):55-60 [9686179.001]
  • [Cites] J Immunol. 1998 Oct 1;161(7):3299-306 [9759845.001]
  • [Cites] J Exp Med. 1998 Oct 19;188(8):1511-20 [9782128.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1811-7 [9973446.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4697-704 [10202010.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):343-7 [10610182.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1414-20 [10751249.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1395-412 [10770805.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1167-75 [11017150.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1176-82 [11017151.001]
  • [Cites] Hum Immunol. 2001 Aug;62(8):753-63 [11476898.001]
  • [Cites] J Immunol. 2001 Sep 1;167(5):2688-93 [11509612.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1635-43 [12070311.001]
  • [Cites] J Immunol. 2003 Jan 15;170(2):870-7 [12517952.001]
  • [Cites] J Autoimmun. 2003 Jun;20(4):265-7 [12791309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11749-54 [15292513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11743-8 [15292514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15434-9 [15492218.001]
  • [Cites] Eur J Immunol. 1971 Aug;1(4):242-8 [5157960.001]
  • [Cites] Eur J Immunol. 1973 May;3(5):273-9 [4128127.001]
  • [Cites] Clin Immunol Immunopathol. 1974 Nov;3(2):256-62 [4141659.001]
  • [Cites] Epidemiol Rev. 1982;4:45-65 [6754409.001]
  • [Cites] N Engl J Med. 1987 Aug 13;317(7):408-14 [3302705.001]
  • [Cites] J Immunol. 1989 Mar 1;142(5):1523-7 [2465343.001]
  • [Cites] Science. 1990 Feb 9;247(4943):718-21 [1689076.001]
  • [Cites] Immunol Today. 1991 Aug;12(8):277-82 [1716903.001]
  • [Cites] Pathobiology. 1991;59(5):305-12 [1716908.001]
  • [Cites] Science. 1992 Nov 27;258(5087):1491-4 [1279812.001]
  • [Cites] Eur J Immunol. 1993 Jan;23(1):17-25 [8419168.001]
  • [Cites] JAMA. 1993 Nov 17;270(19):2362-9 [8230601.001]
  • [Cites] J Exp Med. 1994 Jan 1;179(1):279-90 [7505801.001]
  • [Cites] J Neuroimmunol. 1994 Feb;50(1):95-100 [8300862.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2227-37 [7525850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10859-63 [7526383.001]
  • [Cites] Clin Exp Immunol. 1995 Jul;101 Suppl 1:9-12 [7606862.001]
  • [Cites] J Immunol. 1995 Jul 15;155(2):982-92 [7541828.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):343-6 [8552189.001]
  • (PMID = 15665083.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS030843; United States / NIAID NIH HHS / AI / R01 AI 49524; United States / NIAID NIH HHS / AI / R01 AI049524; United States / NINDS NIH HHS / NS / R01 NS30843; United States / NINDS NIH HHS / NS / R01 NS38037; United States / NINDS NIH HHS / NS / P01 NS038037
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides
  • [Other-IDs] NLM/ PMC547868
  •  go-up   go-down






Advertisement